Sartorius Stedim Biotech S.A. (LON:0RG8)

Market Cap	14.68B -17.3%
Revenue (ttm)	2.57B +7.7%
Net Income	230.35M +64.3%
EPS	2.37 +61.1%
Shares Out	n/a
PE Ratio	63.75
Forward PE	33.86
Dividend	0.58 (0.32%)
Ex-Dividend Date	Apr 2, 2025

Volume	1,734
Average Volume	20,475
Open	178.45
Previous Close	178.00
Day's Range	173.55 - 177.10
52-Week Range	149.70 - 223.20
Beta	1.25
RSI	26.87
Earnings Date	Feb 3, 2026

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog...

• Industry: Laboratory Analytical Instruments
• Founded: 1978
• Employees: 10,134
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RG8

Financial Performance

In 2024, Sartorius Stedim Biotech's revenue was 2.78 billion, an increase of 0.16% compared to the previous year's 2.78 billion. Earnings were 175.10 million, a decrease of -43.57%.

Financial numbers in EUR